CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
filgrastim +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00002825
NCT00002825Phase 2Completed
CompareCT.gov

A PHASE II STUDY OF DOCETAXEL (TAXOTERE) (NSC# 628503) IN CHILDREN WITH RECURRENT SOLID TUMORS

National Cancer Institute (NCI)·interventional·Posted Mar 1, 2004·Updated Feb 5, 2013

In Brief

A Phase 2 clinical trial evaluating filgrastim and docetaxel for Brain and Central Nervous System Tumors and 2 related conditions. Completed, enrolled 20 participants across 36 sites in 3 countries.

Detailed Summary

Phase II trial to study the effectiveness of docetaxel in treating children with recurrent solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain and Central Nervous System Tumors, Neuroblastoma, Sarcoma
CountriesAustralia, Canada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 1, 2004
Enrollment StartJan 1, 1997
Primary CompletionDec 1, 2004
TodayJul 2, 2026
Enrollment to primary: 7.9 yearsPosted 22.3 years ago

Interventions

filgrastimbiological

docetaxeldrug